Archives

  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • 2021-12
  • 2021-11
  • 2021-10
  • 2021-09
  • 2021-08
  • 2021-07
  • 2021-06
  • 2021-05
  • 2021-04
  • 2021-03
  • 2021-02
  • 2021-01
  • 2020-12
  • 2020-11
  • 2020-10
  • 2020-09
  • 2020-08
  • 2020-07
  • 2020-06
  • 2020-05
  • 2020-04
  • 2020-03
  • 2020-02
  • 2020-01
  • 2019-12
  • 2019-11
  • 2019-10
  • 2019-09
  • 2019-08
  • 2019-07
  • 2019-06
  • 2019-05
  • 2019-04
  • 2018-11
  • 2018-10
  • 2018-07

    • NEDD4L Suppresses Colorectal Cancer Liver Metastasis via PRM

    2026-05-27

    NEDD4L Suppresses Colorectal Cancer Liver Metastasis via PRMT5 Degradation

    Study Background and Research Question

    Colorectal cancer (CRC) remains a leading cause of cancer mortality globally, with liver metastasis accounting for the majority of CRC-related deaths. While post-translational modifications, such as ubiquitination, have been implicated in tumor progression, the specific E3 ligases that modulate CRC liver metastasis have not been clearly defined. Previous evidence indicates that dysfunctional E3 ligase activity is frequently associated with cancer, yet the molecular determinants governing metastatic spread, particularly to the liver, require further elucidation. The central research question addressed in the study by Dong et al. (DOI: 10.1002/advs.202504704) is: Which E3 ligase(s) suppress CRC liver metastasis, and through what mechanistic pathway?

    Key Innovation from the Reference Study

    The principal innovation of this research lies in the identification of neural precursor cell expressed developmentally down-regulated gene 4-like (NEDD4L) as a critical suppressor of CRC liver metastasis. Unlike previous studies that broadly associated E3 ligases with cancer, this work systematically screens a focused library of 156 cancer-related E3 ligases in vivo to pinpoint NEDD4L as a negative regulator of metastatic colonization. Mechanistically, the study is the first to demonstrate that NEDD4L directly targets protein arginine methyltransferase 5 (PRMT5) for ubiquitination and subsequent proteasomal degradation, thereby inhibiting AKT/mTOR pathway activation—a signaling axis well-established in cancer cell proliferation and metastasis.

    Methods and Experimental Design Insights

    This investigation employed an in vivo loss-of-function screening approach using a lentiviral shRNA library targeting 156 E3 ubiquitin ligases. Human HCT-15 colorectal cancer cells transduced with individual shRNAs were introduced into a murine model to assess their relative contributions to liver metastasis. Through this systematic screen, NEDD4L was identified as a key suppressor of metastatic potential. Subsequent mechanistic studies used co-immunoprecipitation assays, ubiquitination analysis, and protein stability assays to validate the direct interaction between NEDD4L and PRMT5. The binding site was mapped to the PPNAY motif of PRMT5, confirming substrate specificity. Downstream pathway analyses included immunoblotting for AKT/mTOR signaling components and quantification of CRC cell proliferation and colonization in both in vitro and in vivo models.

    Protocol Parameters

    • shRNA library screening: 794 shRNAs targeting 156 E3 ligases; lentiviral transduction into HCT-15 cells followed by in vivo assessment of liver metastasis.
    • Co-immunoprecipitation: Protein interaction studies performed using HA-tagged constructs and anti-HA antibodies to detect NEDD4L–PRMT5 interaction.
    • Ubiquitination assays: Detection of PRMT5 ubiquitination in the presence of wild-type and E3 ligase-deficient NEDD4L.
    • Pathway analysis: Immunoblotting for AKT/mTOR pathway components post-NEDD4L manipulation.
    • In vivo metastasis model: Tail vein injection of manipulated CRC cells into immunocompromised mice, followed by quantification of liver metastatic nodules.

    Core Findings and Why They Matter

    The screen identified NEDD4L as a repressor of CRC liver metastasis. Mechanistically, NEDD4L binds to the PPNAY motif of PRMT5, catalyzing its ubiquitination and proteasomal degradation. Loss of NEDD4L leads to PRMT5 accumulation, increased arginine methylation of AKT1, and hyperactivation of the AKT/mTOR pathway. This cascade promotes CRC cell proliferation and enhances metastatic colonization in the liver. The study establishes PRMT5 as a direct substrate of NEDD4L and uncovers a critical molecular circuit by which NEDD4L restricts metastatic outgrowth (Dong et al., 2025). These insights advance the understanding of how post-translational regulation intersects with oncogenic signaling to control metastatic dissemination, highlighting NEDD4L-PRMT5-AKT/mTOR as a potential therapeutic axis for intervention.

    Comparison with Existing Internal Articles

    Recent internal reviews, such as those at Perylene-Azide.com and Angiotensin-1-2-1-9.com, discuss the versatility of the Influenza Hemagglutinin (HA) Peptide as an epitope tag for protein detection, immunoprecipitation, and studies of ubiquitination. These resources highlight the peptide’s role in facilitating protein-protein interaction analyses and its relevance to E3 ligase pathway investigations. The current study’s use of HA-tagged constructs and immunoprecipitation with Anti-HA antibodies exemplifies the practical value of this reagent, supporting workflows for mapping interactions and post-translational modifications. While the internal articles focus on the general application of HA tag peptides in molecular biology, the reference study demonstrates their utility in dissecting cancer-relevant ubiquitination mechanisms.

    Limitations and Transferability

    While the findings robustly demonstrate the anti-metastatic function of NEDD4L via PRMT5 degradation in CRC models, several limitations warrant consideration. The study is primarily conducted in a single human CRC cell line (HCT-15) and in murine models, which may not fully capture the heterogeneity of patient tumors or the complexity of human metastasis. Further validation in diverse CRC contexts and clinical samples is necessary to generalize the therapeutic relevance. Additionally, while the degradation of PRMT5 attenuates AKT/mTOR signaling, the broader landscape of NEDD4L substrates and their contributions to metastasis remain to be defined.

    Why this cross-domain matters, maturity, and limitations

    The cross-domain application of epitope tagging and immunoprecipitation—tools originally developed for basic protein detection—has matured into an essential approach for studying post-translational modifications such as ubiquitination in cancer biology. However, the translation of findings from model systems to clinical therapies requires careful validation, and the context-dependent roles of NEDD4L and PRMT5 in other tissues or cancer types are not fully resolved.

    Research Support Resources

    For researchers aiming to investigate protein-protein interactions, ubiquitination, or related post-translational modifications in cancer or other systems, high-purity epitope tags are vital for reliable detection and immunoprecipitation. The Influenza Hemagglutinin (HA) Peptide (SKU A6004) from APExBIO offers a validated option for competitive binding to Anti-HA antibodies and efficient elution of HA-tagged fusion proteins. Its solubility and purity support robust immunoprecipitation and protein purification workflows, as reported in the product information and corroborated by internal reviews. Using such standardized reagents can enhance reproducibility in studies of E3 ligase-substrate interactions and facilitate the translation of mechanistic insights into new research directions.